Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3 study of vepdegestrant in combination with palbociclib and potentially other CDK4/6 inhibitors in a second-line Breast Cancer

Next Previous
X
Search
Trial Profile

A phase 3 study of vepdegestrant in combination with palbociclib and potentially other CDK4/6 inhibitors in a second-line Breast Cancer

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 06 Nov 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Palbociclib (Primary) ; Vepdegestrant (Primary)
  • Indications Breast cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 30 Oct 2024 According to an Arvinas, Inc. media release, company plans to start this Phase 3 combination trial in the second line setting (anticipated in 2025; pending emerging data and regulatory feedback).
    • 27 Feb 2024 According to an Arvinas, Inc. media release, the company is planning to initiate discussion with regulatory authorities on a second-line Phase 3 trial of in combination with and potentially other CDK4/6 inhibitors.
    • 11 Dec 2023 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top